| Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis … CL Vale European urology 48 (2), 202-206, 2005 | 1133 | 2005 |
| Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis C Vale The Lancet 361 (9373), 1927-1934, 2003 | 718 | 2003 |
| Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers VB Lokeshwar, T Habuchi, HB Grossman, WM Murphy, SH Hautmann, ... Urology 66 (6), 35-63, 2005 | 564 | 2005 |
| Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration CL Vale European urology 48 (2), 189-201, 2005 | 497* | 2005 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 402 | 2021 |
| Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma SJ Chatterjee, R Datar, D Youssefzadeh, B George, PJ Goebell, JP Stein, ... Journal of clinical oncology 22 (6), 1007-1013, 2004 | 322 | 2004 |
| Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial JC Araujo, GC Trudel, F Saad, AJ Armstrong, YY Evan, J Bellmunt, ... The lancet oncology 14 (13), 1307-1316, 2013 | 250 | 2013 |
| Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium PJ Goebell, MA Knowles Urologic Oncology: Seminars and Original Investigations 28 (4), 409-428, 2010 | 239 | 2010 |
| Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers T Habuchi, M Marberger, MJ Droller, GP Hemstreet III, HB Grossman, ... Urology 66 (6), 64-74, 2005 | 220 | 2005 |
| Limited survival of adult human testicular tissue as ectopic xenograft S Schlatt, A Honaramooz, J Ehmcke, PJ Goebell, H Rübben, R Dhir, ... Human reproduction 21 (2), 384-389, 2006 | 190 | 2006 |
| Efficacy and safety of TachoSil® as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study S Siemer, S Lahme, S Altziebler, S Machtens, W Strohmaier, HW Wechsel, ... european urology 52 (4), 1156-1163, 2007 | 174 | 2007 |
| p53 immunohistochemistry as a prognostic marker in bladder cancer: Playground for urology scientists? BJ Schmitz-Dräger, PJ Goebell, T Ebert, Y Fradet European urology 38 (6), 691-700, 2000 | 171 | 2000 |
| SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal … C Eichelberg, WL Vervenne, M De Santis, LF von Weikersthal, PJ Goebell, ... European urology 68 (5), 837-847, 2015 | 161 | 2015 |
| Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised … T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, ... The lancet oncology 23 (9), 1133-1144, 2022 | 154 | 2022 |
| Statistical consideration for clinical biomarker research in bladder cancer SF Shariat, Y Lotan, A Vickers, PI Karakiewicz, BJ Schmitz-Dräger, ... Urologic Oncology: Seminars and Original Investigations 28 (4), 389-400, 2010 | 143 | 2010 |
| The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer M Richterstetter, B Wullich, K Amann, L Haeberle, DG Engehausen, ... BJU international 110 (2b), E76-E79, 2012 | 124 | 2012 |
| 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer C Schmidkonz, M Cordes, D Schmidt, T Bäuerle, TI Goetz, M Beck, ... European journal of nuclear medicine and molecular imaging 45, 1862-1872, 2018 | 121 | 2018 |
| Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer SJ Chatterjee, B George, PJ Goebell, M Alavi‐Tafreshi, SR Shi, YK Fung, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2004 | 113 | 2004 |
| Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases HM Fritsche, M Burger, S Denzinger, W Legal, PJ Goebell, A Hartmann The Journal of urology 180 (5), 1923-1927, 2008 | 94 | 2008 |
| p53 and MDM2 in the development and progression of bladder cancer BJ Schmitz-Dräger, M Kushima, P Goebell, TW Jax, CD Gerharz, H Bültel, ... European urology 32 (4), 487-493, 1997 | 93 | 1997 |
Philipp RittHead of Imaging & Dosimetry, ITM Isotope Technologies Munich SE, GermanyVerified email at itm-radiopharma.com
